Kadmon (NYSE:KDMN) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a report issued on Tuesday, January 16th.
According to Zacks, “Kadmon Holdings, Inc. is a biopharmaceutical company. It engaged in the discovery, development and commercialization of small molecules and biologics to address disease areas of significant unmet medical need. The company is developing product candidates within autoimmune and fibrotic diseases, oncology and genetic diseases. Kadmon Holdings, Inc. is headquartered in New York. “
A number of other brokerages also recently issued reports on KDMN. WBB Securities downgraded shares of Kadmon from a “hold” rating to a “sell” rating and set a $3.00 price target for the company. in a report on Monday, October 9th. HC Wainwright restated a “buy” rating and set a $25.00 price target on shares of Kadmon in a report on Friday, November 17th. Three investment analysts have rated the stock with a sell rating, one has issued a hold rating and two have issued a buy rating to the company. The stock has an average rating of “Hold” and an average price target of $8.65.
Kadmon (NYSE:KDMN) traded down $0.17 during mid-day trading on Tuesday, reaching $4.79. 667,065 shares of the company’s stock were exchanged, compared to its average volume of 1,278,436. The firm has a market cap of $376.70, a P/E ratio of -2.74 and a beta of 5.39. Kadmon has a 12 month low of $2.05 and a 12 month high of $5.86.
Kadmon (NYSE:KDMN) last released its quarterly earnings data on Thursday, November 9th. The company reported ($0.42) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.38) by ($0.04). The business had revenue of $2.28 million for the quarter, compared to the consensus estimate of $5.69 million. The company’s revenue was down 60.0% compared to the same quarter last year. During the same period last year, the firm posted ($4.24) EPS. analysts predict that Kadmon will post -1.62 EPS for the current year.
Several large investors have recently bought and sold shares of KDMN. Goldman Sachs Group Inc. purchased a new position in shares of Kadmon during the 2nd quarter worth approximately $114,000. Bank of New York Mellon Corp purchased a new position in Kadmon in the 3rd quarter valued at approximately $119,000. Old West Investment Management LLC purchased a new position in Kadmon in the 3rd quarter valued at approximately $169,000. Wells Fargo & Company MN boosted its position in Kadmon by 17.0% in the 2nd quarter. Wells Fargo & Company MN now owns 60,033 shares of the company’s stock valued at $234,000 after buying an additional 8,742 shares during the period. Finally, BlackRock Inc. boosted its position in Kadmon by 151.2% in the 4th quarter. BlackRock Inc. now owns 208,190 shares of the company’s stock valued at $754,000 after buying an additional 125,308 shares during the period. 51.91% of the stock is owned by hedge funds and other institutional investors.
Kadmon Company Profile
Kadmon Holdings, Inc is an integrated biopharmaceutical company engaged in the discovery, development and commercialization of small molecules and biologics to address disease areas of various unmet medical needs. The Company is developing product candidates in a number of indications within autoimmune and fibrotic disease, oncology and genetic diseases.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Kadmon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kadmon and related companies with MarketBeat.com's FREE daily email newsletter.